Evusheld (Bebtelovimab)
Experts are hopeful that this preventive medication, taken before any exposure to COVID-19, will provide an extra layer of protection to those who may not mount a full immune response to the vaccine - Kelsey Kloss
.jpg)
image by: The Elliot Lewis Center
HWN Recommends
What to Know About Evusheld, the New Monoclonal Antibody Drug to Prevent COVID-19 in the Immunocompromised
Over the course of the pandemic, many immunocompromised patients have not been able to rejoin activities, events, and travel as fully as the general population — even if they’re fully vaccinated. That’s because people with certain underlying conditions or who take medications that affect their immune system might not mount a full response to the COVID-19 vaccine.
But now, the U.S. Food & Drug Administration (FDA) has issued an emergency use authorization (EUA) for long-acting monoclonal antibodies that can be used to prevent COVID-19 before exposure in immunocompromised individuals.
This product, AstraZeneca’s Evusheld, contains tixagevimab and cilgavimab — monoclonal antibodies…
Resources
Evusheld (formerly AZD7442) long-acting antibody combination authorised for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19
Only antibody therapy authorised in US for pre-exposure prophylaxis. Pivotal phase III data showed robust efficacy and long-term protection with one dose in high-risk population.
Hospitals use a lottery to allocate scarce COVID drugs for the immunocompromised
The government provides Evusheld to states based on their total adult populations. The approach doesn't prioritize where the need is greatest.
‘I felt this huge relief’: how antibody injections could free the immunosuppressed under Covid
FDA expected to issue full emergency authorization for periodic antibody injections, or PrEP, to complement vaccinations.
What to Know About Evusheld, the New Monoclonal Antibody Drug to Prevent COVID-19 in the Immunocompromised
Experts are hopeful that this preventive medication, taken before any exposure to COVID-19, will provide an extra layer of protection to those who may not mount a full immune response to the vaccine.
Evusheld
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product EVUSHELDTM (tixagevimab co-packaged with cilgavimab) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and pediatric individuals (12 years of age and older weighing at least 40 kg)...
Related Articles
Stay Connected
©2022 | HealthWorldNet, Inc. | 116388
Last Updated : Sunday, February 20, 2022